Arbutus Biopharma (ABUS) Non Operating Income (2015 - 2026)

Arbutus Biopharma has reported Non Operating Income for 12 years, with the latest figure at $787000.0 in Q1 2026.

• Quarterly Non Operating Income fell 32.91% year-over-year to $787000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.3 million (down 29.77% YoY) and the FY2025 annual result came in at $4.7 million, down 27.19% from the prior year.
• Non Operating Income retreated to $787000.0 in Q1 2026 per ABUS's latest filing, from $1.5 million in the prior quarter.
• Over five years, Non Operating Income peaked at $1.8 million in Q2 2024 and troughed at -$347000.0 in Q1 2022.
• A 5-year average of $1.0 million and a median of $1.2 million in 2025 frame the typical range for Non Operating Income.
• The sharpest annual moves came in 2023 and 2025: Non Operating Income soared 1655.42% in 2023, then tumbled 46.78% in 2025.
• Over 5 years, Non Operating Income stood at $630000.0 in 2022, then jumped by 127.78% to $1.4 million in 2023, then decreased by 2.37% to $1.4 million in 2024, then increased by 9.49% to $1.5 million in 2025, then sank by 48.7% to $787000.0 in 2026.
• According to Business Quant data, Non Operating Income over the past three periods registered $787000.0, $1.5 million, and $917000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.